PE/Cy7® Anti-CD161 antibody [PK136],Abcam,AB241100

The antibody is reported to react with an epitope common to NKR-P1B and NKR-P1C alloantigenic forms of CD161 (NK1.1). This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5, 268, 486 and related patents. Cy® and CyDye® are trademarks of Cytiva.

Host

Mouse

Reactivity

Mouse

Application

Flow Cyt

Conjugate

PE/Cy7®

Platform ID

BAB735947249

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Abcam

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Email:

[email protected]

Product Specifications
Scientific Background

Specifications

NamePE/Cy7® Anti-CD161 antibody [PK136]
Cat. No.AB241100
HostMouse
IsotypeIgG2a
ReactivityMouse
ConjugationPE/Cy7®
ApplicationFlow Cyt
ClonalityMonoclonal
Clone NumberPK136
Concentration0.2 - 0.5 mg/mL Batch dependent concentration
PurityAffinity purification
Appearance/FormLiquid
ShippingBlue Ice
FormulationpH: 7.2 Preservative: 0.09% Sodium azide Constituents: 0.87% Sodium chloride, 0.12% Sodium dihydrogen phosphate, 0.1% Gelatin
Storage+4°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Plays an inhibitory role on natural killer (NK) cells cytotoxicity. Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide. Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3. Acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope as well as to the N-acetyllactosamine epitope. Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells. See full target information KLRB1

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.